Impax Asset Management Group PLC Exelixis, Inc. Transaction History

Impax Asset Management Group PLC

  • $23 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 12, 2021
SELL
$16.3 - $21.14 $2.12 Million - $2.74 Million
-129,756 Closed
0 $0
Q2 2021

Aug 05, 2021
SELL
$17.95 - $25.56 $4.85 Million - $6.91 Million
-270,244 Reduced 67.56%
129,756 $2.36 Million
Q1 2021

May 14, 2021
BUY
$20.53 - $25.22 $3.08 Million - $3.78 Million
150,000 Added 60.0%
400,000 $9.04 Million
Q2 2020

Aug 14, 2020
BUY
$16.46 - $27.42 $4.12 Million - $6.86 Million
250,000 New
250,000 $5.94 Million

Others Institutions Holding EXEL

# of Institutions
507
Shares Held
243M
Call Options Held
2.54M
Put Options Held
2.29M
View Full List

About EXELIXIS, INC.

EXEL Quotes by TradingView
  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $11.7B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Impax Asset Management Group PLC Portfolio

Follow Impax Asset Management Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Impax Asset Management Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Impax Asset Management Group PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email